751 related articles for article (PubMed ID: 33167990)
1. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
3. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
[TBL] [Abstract][Full Text] [Related]
4. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
Shin H; Schneeweiss S; Glynn RJ; Patorno E
Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
Real J; Vlacho B; Ortega E; Vallés JA; Mata-Cases M; Castelblanco E; Wittbrodt ET; Fenici P; Kosiborod M; Mauricio D; Franch-Nadal J
Cardiovasc Diabetol; 2021 Jul; 20(1):139. PubMed ID: 34243779
[TBL] [Abstract][Full Text] [Related]
7. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
8. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
McCormick N; Yokose C; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; McCoy RG; Choi HK
JAMA Intern Med; 2024 Jun; 184(6):650-660. PubMed ID: 38619822
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
12. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
14. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Shao SC; Chang KC; Hung MJ; Yang NI; Chan YY; Chen HY; Kao Yang YH; Lai EC
Cardiovasc Diabetol; 2019 Sep; 18(1):120. PubMed ID: 31551068
[TBL] [Abstract][Full Text] [Related]
16. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
17. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
[TBL] [Abstract][Full Text] [Related]
18. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
[TBL] [Abstract][Full Text] [Related]
19. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
[TBL] [Abstract][Full Text] [Related]
20. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
